StreetInsider.com News Articles

Form 4 Actinium Pharmaceuticals For: Oct 14 Filed by: David Matthew T

Fri, 16 Oct 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20261016/27198653.html

Form 3 Actinium Pharmaceuticals For: Oct 14 Filed by: David Matthew T

Fri, 16 Oct 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20261016/27198645.html

Actinium Pharmaceuticals Announces Inducement Grants to New Employees

Fri, 16 Oct 2026 17:00:00 -0400

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement equity awards to Matt David, M.D., the Company's newly appointed Chief Financial Officer, and Sean Maenpaa, the Company's newly appointed Senior Vice President, Business Development.

Actinium Pharmaceuticals Announces Inducement Grants to New Employees

Fri, 16 Oct 2026 17:00:00 -0400

Actinium to present ATNM-400 cancer data at EANM 2026

Fri, 16 Oct 2026 08:31:01 -0400

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) will present preclinical data on its Actinium-225 radiotherapy candidate ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), held October 17–21, 2026, in Vienna, Austria.

The company will deliver one oral presentation and two e-poster presentations covering ATNM-400 activity in non-small cell lung cancer (NSCLC), colorectal cancer, and ovarian cancer models.

The oral presentation, scheduled for October 19, will cover ATNM-400 activity in KRAS- and ALK-driven NSCLC models, including in resistant models. The data extend earlier findings in EGFR-mutant NSCLC and are intended to support a mutation-agnostic development approach.

In colorectal cancer,

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

Fri, 16 Oct 2026 08:30:00 -0400

Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development
Colorectal cancer data demonstrate ATNM-400's potential to enhance responses to standard-of-care therapies

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

Fri, 16 Oct 2026 08:30:00 -0400

Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development
Colorectal cancer data demonstrate ATNM-400's potential to enhance responses to standard-of-care therapies

Form ARS Actinium Pharmaceuticals For: Dec 31

Fri, 16 Oct 2026 07:51:00 -0400

si-local-file:///var/storage/secattach/20261016/27195772.html

Form DEF 14A Actinium Pharmaceuticals For: Nov 25

Fri, 16 Oct 2026 07:43:00 -0400

si-local-file:///var/storage/secattach/20261016/27195735.html

Actinium Pharmaceuticals names Sean Maenpaa as SVP of business development

Fri, 16 Oct 2026 07:30:42 -0400

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) has appointed Sean Maenpaa as Senior Vice President, Business Development, effective October 12, 2026, according to a company statement.

Maenpaa will oversee out-licensing, partnering, collaboration transactions, in-licensing opportunities, and corporate development strategy for Actinium's targeted radiotherapy pipeline.

Maenpaa brings more than 20 years of experience in oncology business development and commercial leadership across the radiopharmaceutical sector. He previously served as Managing Director of Maenpaa Consulting LLC, providing strategic support to private equity and investment banks focused on oncology radiopharmaceuticals.

Before his consultancy, Maenpaa was Vice President, Commercial, at BWXT Medical, where he oversaw business development and sales

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

Fri, 16 Oct 2026 07:30:00 -0400

– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals and BWXT Medical

– Will lead partnering, licensing and strategic transactions across Actinium's targeted radiotherapy pipeline

NEW YORK,

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

Fri, 16 Oct 2026 07:30:00 -0400

– Will lead partnering, licensing and strategic transactions across Actinium's targeted radiotherapy pipeline

NEW YORK,

Form 8-K Actinium Pharmaceuticals For: Oct 14

Thu, 15 Oct 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20261015/27194105.html

Actinium to present Phase 1 data on ATNM-400 at EANM 2026

Thu, 15 Oct 2026 08:30:49 -0400

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced that early results from a first-in-human Phase 1 study of its experimental cancer treatment ATNM-400 will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), held October 17–21, 2026, in Vienna, Austria.

The oral presentation, scheduled for October 19, 2026, will cover the ongoing Phase 1 dose-escalation study of ATNM-400 in metastatic castration-resistant prostate cancer (mCRPC). ATNM-400 is an Actinium-225 antibody radioconjugate that targets a non-PSMA antigen associated with tumor survival and treatment resistance.

The study uses a Zirconium-89-labeled version of ATNM-400 to evaluate safety, biodistribution, and dosimetry through

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Thu, 15 Oct 2026 08:30:00 -0400

Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC)
Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry to inform the development of Actinium-225-labeled ATNM-400 as a

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Thu, 15 Oct 2026 08:30:00 -0400

Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC)
Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry to inform the development of Actinium-225-labeled ATNM-400 as a

Actinium Pharmaceuticals names Matt David as CFO

Thu, 15 Oct 2026 07:31:14 -0400

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) appointed Matt David, M.D., as Chief Financial Officer, the company announced Oct. 15, 2026. Dr. David will oversee finance, accounting, capital markets and investor relations, and will serve as the company's principal financial officer.

Dr. David joins Actinium from CorMedix Inc. (Nasdaq: CRMD), where he most recently served as Executive Vice President and Chief Business Officer. He joined CorMedix in 2020 as Executive Vice President and Chief Financial Officer. During his time there, CorMedix received U.S. Food and Drug Administration approval of DefenCath® in 2023, launched the product commercially in 2024, and acquired a commercial

Actinium Pharmaceuticals names Matt David as CFO

Thu, 15 Oct 2026 07:31:14 -0400

Actinium Pharmaceuticals names Matt David as CFO

Thu, 15 Oct 2026 07:31:14 -0400

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer